グラチラマー薬の世界市場2020-2026:ブランド薬、ジェネリック医薬品

QYResearchが発行した調査報告書(QYR20AP00868)
◆英語タイトル:Global Glatiramer Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP00868
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:118
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、グラチラマー薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、グラチラマー薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(ブランド薬、ジェネリック医薬品)、用途別市場規模(病院、薬局、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・グラチラマー薬の種類別市場2015-2026:ブランド薬、ジェネリック医薬品
・グラチラマー薬の用途別市場2015-2026:病院、薬局、その他
・グラチラマー薬の北米市場分析
・グラチラマー薬のアジア市場分析
・グラチラマー薬の中南米市場分析
・グラチラマー薬の中東・アフリカ市場分析
・関連企業情報:Teva、NATCO Pharma、Mylan、Novartis、HYBIO
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Glatiramer is an immunomodulator medication currently used to treat multiple sclerosis.In 2019, the global Glatiramer Drugs market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of xx% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Glatiramer Drugs.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Glatiramer Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Glatiramer Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Glatiramer Drugs market. Readers of the report can become informed about current and future trends of the global Glatiramer Drugs market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Glatiramer Drugs markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Glatiramer Drugs market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Glatiramer Drugs market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Glatiramer Drugs market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Glatiramer Drugs market is segmented into
Brand Medicine
Generic Drug

Market Segment by Application, the Glatiramer Drugs market is segmented into
Hospital
Pharmacy
Other

This report includes the following manufacturers; we can also add the other companies as you want.
Teva
NATCO Pharma
Mylan
Novartis
HYBIO

The study objectives are:
To analyze and research the global Glatiramer Drugs status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Glatiramer Drugs manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Glatiramer Drugs are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Glatiramer Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Glatiramer Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Brand Medicine
1.3.3 Generic Drug
1.4 Market Segment by Application
1.4.1 Global Glatiramer Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Glatiramer Drugs Revenue (2015-2026)
2.1.1 Global Glatiramer Drugs Revenue (2015-2026)
2.1.2 Global Glatiramer Drugs Sales (2015-2026)
2.2 Glatiramer Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Glatiramer Drugs Sales by Regions (2015-2020)
2.2.2 Global Glatiramer Drugs Revenue by Regions (2015-2020)
2.3 Global Top Glatiramer Drugs Regions (Countries) Ranking by Market Size
2.4 Glatiramer Drugs Industry Trends
2.4.1 Glatiramer Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Glatiramer Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Glatiramer Drugs Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Glatiramer Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Glatiramer Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Glatiramer Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Glatiramer Drugs Sales in 2019
3.2 Global Top Manufacturers Glatiramer Drugs by Revenue
3.2.1 Global Glatiramer Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Glatiramer Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Glatiramer Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glatiramer Drugs as of 2019)
3.4 Global Glatiramer Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Glatiramer Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Glatiramer Drugs Market
3.7 Key Manufacturers Glatiramer Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Glatiramer Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Glatiramer Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Glatiramer Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Glatiramer Drugs Price by Type (2015-2020)
4.1 Global Glatiramer Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Glatiramer Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Glatiramer Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Glatiramer Drugs Price Forecast by Type (2021-2026)

5 Global Glatiramer Drugs Market Size by Application
5.1 Global Glatiramer Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Glatiramer Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Glatiramer Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Glatiramer Drugs Price by Application (2015-2020)
5.2 Global Glatiramer Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Glatiramer Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Glatiramer Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Glatiramer Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Glatiramer Drugs Breakdown Data by Company
6.2 North America Glatiramer Drugs Breakdown Data by Type
6.3 North America Glatiramer Drugs Breakdown Data by Application
6.4 North America Glatiramer Drugs Breakdown Data by Countries
6.4.1 North America Glatiramer Drugs Sales by Countries
6.4.2 North America Glatiramer Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Glatiramer Drugs Breakdown Data by Company
7.2 Europe Glatiramer Drugs Breakdown Data by Type
7.3 Europe Glatiramer Drugs Breakdown Data by Application
7.4 Europe Glatiramer Drugs Breakdown Data by Countries
7.4.1 Europe Glatiramer Drugs Sales by Countries
7.4.2 Europe Glatiramer Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Glatiramer Drugs Breakdown Data by Company
8.2 Asia Pacific Glatiramer Drugs Breakdown Data by Type
8.3 Asia Pacific Glatiramer Drugs Breakdown Data by Application
8.4 Asia Pacific Glatiramer Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Glatiramer Drugs Sales by Regions
8.4.2 Asia Pacific Glatiramer Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Glatiramer Drugs Breakdown Data by Company
9.2 Latin America Glatiramer Drugs Breakdown Data by Type
9.3 Latin America Glatiramer Drugs Breakdown Data by Application
9.4 Latin America Glatiramer Drugs Breakdown Data by Countries
9.4.1 Latin America Glatiramer Drugs Sales by Countries
9.4.2 Latin America Glatiramer Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Glatiramer Drugs Breakdown Data by Type
10.2 Middle East and Africa Glatiramer Drugs Breakdown Data by Application
10.3 Middle East and Africa Glatiramer Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Glatiramer Drugs Sales by Countries
10.3.2 Middle East and Africa Glatiramer Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Teva
11.1.1 Teva Corporation Information
11.1.2 Teva Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Teva Glatiramer Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Teva Glatiramer Drugs Products and Services
11.1.5 Teva SWOT Analysis
11.1.6 Teva Recent Developments
11.2 NATCO Pharma
11.2.1 NATCO Pharma Corporation Information
11.2.2 NATCO Pharma Business Overview and Total Revenue (2019 VS 2018)
11.2.3 NATCO Pharma Glatiramer Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 NATCO Pharma Glatiramer Drugs Products and Services
11.2.5 NATCO Pharma SWOT Analysis
11.2.6 NATCO Pharma Recent Developments
11.3 Mylan
11.3.1 Mylan Corporation Information
11.3.2 Mylan Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Mylan Glatiramer Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Mylan Glatiramer Drugs Products and Services
11.3.5 Mylan SWOT Analysis
11.3.6 Mylan Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Novartis Glatiramer Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Novartis Glatiramer Drugs Products and Services
11.4.5 Novartis SWOT Analysis
11.4.6 Novartis Recent Developments
11.5 HYBIO
11.5.1 HYBIO Corporation Information
11.5.2 HYBIO Business Overview and Total Revenue (2019 VS 2018)
11.5.3 HYBIO Glatiramer Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 HYBIO Glatiramer Drugs Products and Services
11.5.5 HYBIO SWOT Analysis
11.5.6 HYBIO Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Glatiramer Drugs Sales Channels
12.2.2 Glatiramer Drugs Distributors
12.3 Glatiramer Drugs Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Glatiramer Drugs Sales Forecast (2021-2026)
13.1.1 Global Glatiramer Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Glatiramer Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Glatiramer Drugs Sales Forecast (2021-2026)
13.2.2 North America Glatiramer Drugs Revenue Forecast (2021-2026)
13.2.3 North America Glatiramer Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Glatiramer Drugs Sales Forecast (2021-2026)
13.3.2 Europe Glatiramer Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Glatiramer Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Glatiramer Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Glatiramer Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Glatiramer Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Glatiramer Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Glatiramer Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Glatiramer Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Glatiramer Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Glatiramer Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Glatiramer Drugs Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Teva、NATCO Pharma、Mylan、Novartis、HYBIO

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ グラチラマー薬の世界市場2020-2026:ブランド薬、ジェネリック医薬品(Global Glatiramer Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。